Modulation of AD neuropathology and memory impairments by the isoprostane F2α is mediated by the thromboxane receptor

Neurobiology of Aging

Volumn 36, Issue 2, 2015, Pages 812-820

  Lauretti, Elisabetta ^a   Di Meco, Antonio ^a   Chu, Jin ^a   Praticò, Domenico ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Isoprostanes; Lipid peroxidation; Oxidative stress; Tau; Transgenic mouse models

Indexed keywords

8 ISOPROSTANE F2ALPHA; AMYLOID BETA PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE 5; ISOPROSTANE DERIVATIVE; TAU PROTEIN; THROMBOXANE RECEPTOR; UNCLASSIFIED DRUG; 8-EPI-PROSTAGLANDIN F2ALPHA; PROSTAGLANDIN F2 ALPHA;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMORY DISORDER; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; ANALOGS AND DERIVATIVES; ANIMAL; BEHAVIOR; BRAIN; COGNITION; DISEASE MODEL; GENETICS; HUMAN; MEMORY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PSYCHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BEHAVIOR; BRAIN; COGNITION; DINOPROST; DISEASE MODELS, ANIMAL; HUMANS; MEMORY; MICE, TRANSGENIC; OXIDATIVE STRESS; PHOSPHORYLATION; RECEPTORS, THROMBOXANE; TAU PROTEINS;

EID: 84922825340     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.10.005     Document Type: Article

References (29)

1. Agostinho P., Cunha R.A., Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr. Pharm. Des. 2010, 16:2766-2778.
2. Bianchi D., De Michele P., Marchetti C., Tirozzi B., Cuomo S., Marie H., Migliore M. Effects of increasing CREB-dependent transcription on the storage and recall processes in a hippocampal CA1 microcircuit. Hippocampus 2014, 24:165-177.
3. Chu J., Lauretti E., Craige C.P., Praticò D. Pharmacological modulation of GSAP reduces amyloid-ß levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles. J.Alzheimers Dis. 2014, 41:729-737.
4. Evans A.R., Junger H., Southall M.D., Nicol G.D., Sorkin L.S., Broome J.T., Bailey T.W., Vasko M.R. Isoprostanes, novel eicosanoids that produce nociception and sensitize rat sensory neurons. J.Pharmacol. Exp. Ther. 2000, 293:912-920.
5. Gandy S. Lifelong management of amyloid beta metabolism to prevent Alzheimer's disease. N.Engl. J. Med. 2012, 367:864-866.
6. Giannopoulos P.F., Chu J., Joshi Y.B., Sperow M., Li J.G., Kirby L.G., Praticò D. Gene knockout of 5-lipoxygenase rescues synaptic dysfunction and improves memory in the triple-transgenic model of Alzheimer's disease. Mol. Psych. 2014, 19:511-518.
7. Giannopoulos P.F., Joshi Y.B., Chu J., Praticò D. The 12/15lipoxygenase is a modulator of Alzheimer's related tau pathology invivo. Aging Cell 2013, 12:1082-1090.
8. Hirata-Fukae C., Li H.F., Hoe H.S., Gray A.J., Minami S.S., Hamada K., Niikura T., Hua F., Tsukagoshi-Nagai H., Horikoshi-Sakuraba Y., Mughal M., Rebeck G.W., LaFerla F.M., Mattson M.P., Iwata N., Saido T.C., Klein W.L., Duff K.E., Aisen P.S., Matsuoka Y. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 2008, 1216:92-103.
9. Iqbal K., Liu F., Gong C.X., Grundke-Iqbal I. Tau in Alzheimer's disease and related tauopathies. Curr. Alz. Res. 2010, 7:656-664.
10. Joshi Y.B., Giannopoulos P.F., Chu J., Praticò D. Modulation of LPS-induced memory insult, γ-secretase and neuroinflammation in 3xTg mice by 5-lipoxygenase. Neurobiol. Aging 2014, 35:1024-1031.
11. King D.L., Arendash G.W. Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Psysiol. Behav. 2002, 75:627-642.
12. Montine T., Markesbery W., Morrow J., Roberts L. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Ann. Neurol. 1998, 44:410-413.
13. Nakahata N., Ishimoto H., Kurita M., Ohmori K., Takahashi A., Nakanishi H. The presence of thromboxane A2 receptors in cultured astrocytes from rabbit brain. Brain Res. 1992, 583:100-104.
14. Obara Y., Kurose H., Nakahata N. Thromboxane A2 promotes interleukin-6 biosynthesis mediated by an activation of cyclic AMP-response element-binding protein in 1321N1 human astrocytoma cells. Mol. Pharmacol. 2005, 68:670-679.
15. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
16. Oddo S., Caccamo A., Tseng B., Cheng D., Vasilevko V., Cribbs D.H., LaFerla F.M. Blocking Abeta 42 accumulation delays the onset and progression of tau pathology via the C terminus of the heat shock protein 70-interacting protein: a mechanistic link between Abeta and tau pathology. J.Neurosci. 2008, 28:12163-12175.
17. Praticò D. Oxidative stress hypothesis in Alzheimer's disease: a reappraisal. Trends Pharmacol. Sci. 2008, 29:609-615.
18. Pratico D., Sung S. Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J.Alzheimers Dis. 2004, 6:171-175.
19. Polidori M.C., Griffiths H.R., Mariani E., Mecocci P. Hallmarks of protein oxidative damage in neurodegenerative diseases: focus on Alzheimer's disease. Amino Acids 2007, 32:553-559.
20. Praticò D. The neurobiology of isoprostanes and Alzheimer's disease. Biochim. Biophys. Acta 2010, 180:930-933.
21. Praticò D., Clark C., Liu F., Lee V., Trojanowski J. Increased of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer's disease. Arch. Neurol. 2002, 59:972-976.
22. Praticò D., Lee V., Trojanowski J., Rokach J., Fitzgerald G. Increased F2-isoprostanes in Alzheimer's disease: evidence of enhanced lipid peroxidation invivo. FASEB J. 1998, 12:1777-1783.
23. Praticò D., Uryu K., Leight S., Trojanowski J., Lee V. Increased lipid peroxidation precedes amyloid plaques formation in an animal model of Alzheimer's amyloidosis. J.Neurosci. 2001, 21:4183-4187.
24. Shineman D., Zhang B., Leight S.N., Praticò D., Lee V. Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice. J.Neurosci. 2008, 28:4785-4794.
25. Strocchi P., Pession A., Dozza B. Up-regulation of cdk5/p35 by oxidative stress in human neuroblastoma IMR-32 cells. J.Cell. Biochem. 2003, 88:758-765.
26. Sung S., Yao Y., Uryu K., Yang H., Lee V., Trojanowski J., Pratico' D. Early vitamin E supplementation in young but not aged mice reduces Aβ levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J. 2004, 18:323-325.
27. Utreras E., Futatsugi A., Rudrabhata P., Keller J., Iadarola M.J., Pant H.C., Kulkarni A.B. Tumor necrosis factor-α regulates cyclin-dependent kinase 5 activity during pain signaling through transcriptional activation of p35. J.Biol. Chem. 2009, 284:2275-2284.
28. Wyss-Coray T., Mucke L. Inflammation in neurodegenerative disease - a double-edge sword. Neuron 2002, 35:419-432.
29. Yamamoto-Sasaki M., Ozawa H., Saito T., Rösler M., Riederer P. Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res. 1999, 824:300-303.